Elena V. Khazova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elena V. Khazova has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Olga V. Boulashova
Kazan State Medical University
13 shared publications - Julia Vladimirovna Oslopova
Kazan (Volga Region) Federal University
8 shared publications - Vladimir N. Oslopov
Kazan State Medical University
8 shared publications - D. V. Oslopova
Kazan State Medical University
6 shared publications - Niyaz R. Khasanov
Kazan State Medical University
5 shared publications - Yuliana S. Mishanina
Kazan State Medical University
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (5) , 700-710
Serotonergic dysregulation: a path to early diagnosis of cardiorenal syndrome
Cardiorenal syndrome remains one of the most complex and unresolved challenges in modern clinical medicine, associated with high mortality, frequent complications, and an unfavorable long-term prognosis for patients. Existing clinical guidelines do not solve the main problem: the biomarkers currently used in routine practice—serum creatinine, estimated glomerular filtration rate, and natriuretic peptides—respond to already established organ damage, predominantly of a single organ, or reflect systemic pathology as a whole, but they do not allow detection of preclinical shifts in inter-organ regulation at early stages. In this context, serotonin (5-hydroxytryptamine, 5-HT) is considered a promising integrative biomarker potentially capable of filling the existing diagnostic niche. To analyze current data on peripheral 5-HT metabolism, its active involvement in endothelial dysfunction, platelet-dependent inflammation, myocardial and renal tissue remodeling, and atherogenesis, 39 full-text publications (2000–2025) were selected from eLibrary.Ru and PubMed using the keywords “серотонин” (serotonin), “хроническая сердечная недостаточность” (chronic heart failure), and “хроническая болезнь почек” (chronic kidney disease). Special attention in this review is given to the phenomenon of opposite-directional changes in 5-HT levels in chronic heart failure and chronic kidney disease—an apparent contradiction that, on closer examination, becomes a potentially valuable diagnostic resource. Serotonin itself, its specific receptors, and major metabolites (5-HIAA, SERT, 5-HT1B/2A/2B/4 receptors) are discussed as candidates for the role of early markers of cardiorenal syndrome. At the same time, the current evidence base remains fragmentary: prospective studies assessing serotonin dynamics at different stages of cardiorenal syndrome are lacking, clinical reference intervals have not been defined, and the comparative informative value of plasma and platelet pools has not been investigated. Further validation of serotonin as a biomarker and study of the possibilities of pharmacological modulation of its receptors may open new approaches to early diagnosis and pathogenetic therapy of cardiorenal syndrome.
- 9 October 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (5) , 700-710
Open AccessSerotonergic dysregulation: a path to early diagnosis of cardiorenal syndrome
Cardiorenal syndrome remains one of the most complex and unresolved challenges in modern clinical medicine, associated with high mortality, frequent complications, and an unfavorable long-term prognosis for patients. Existing clinical guidelines do not solve the main problem: the biomarkers currently used in routine practice—serum creatinine, estimated glomerular filtration rate, and natriuretic peptides—respond to already established organ damage, predominantly of a single organ, or reflect systemic pathology as a whole, but they do not allow detection of preclinical shifts in inter-organ regulation at early stages. In this context, serotonin (5-hydroxytryptamine, 5-HT) is considered a promising integrative biomarker potentially capable of filling the existing diagnostic niche. To analyze current data on peripheral 5-HT metabolism, its active involvement in endothelial dysfunction, platelet-dependent inflammation, myocardial and renal tissue remodeling, and atherogenesis, 39 full-text publications (2000–2025) were selected from eLibrary.Ru and PubMed using the keywords “серотонин” (serotonin), “хроническая сердечная недостаточность” (chronic heart failure), and “хроническая болезнь почек” (chronic kidney disease). Special attention in this review is given to the phenomenon of opposite-directional changes in 5-HT levels in chronic heart failure and chronic kidney disease—an apparent contradiction that, on closer examination, becomes a potentially valuable diagnostic resource. Serotonin itself, its specific receptors, and major metabolites (5-HIAA, SERT, 5-HT1B/2A/2B/4 receptors) are discussed as candidates for the role of early markers of cardiorenal syndrome. At the same time, the current evidence base remains fragmentary: prospective studies assessing serotonin dynamics at different stages of cardiorenal syndrome are lacking, clinical reference intervals have not been defined, and the comparative informative value of plasma and platelet pools has not been investigated. Further validation of serotonin as a biomarker and study of the possibilities of pharmacological modulation of its receptors may open new approaches to early diagnosis and pathogenetic therapy of cardiorenal syndrome.
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 483-485
Clinical masks of T-cell lymphoma
Some progress has been made in the study of the pathogenesis of peripheral T-cell lymphomas, which account for 10–15% of all non-Hodgkin’s lymphomas; however, diagnosis is diffi cult due to their rare occurrence and clinical and morphological diversity. Aim . to present data on the clinical course of peripheral T-cell lymphoma using a clinical example of patient Z. Material and methods. An analysis of literary sources was conducted and a case was presented demonstrating the difficulties in diagnosing non-Hodgkin’s T-cell lymphoma. Results and discussion. Patient Z., 56 years old, treated in a multidisciplinary hospital with the diagnosis of “Acute toxicoderma. Stevens–Johnson syndrome?” had been under the care of a dermatologist for dermatitis for 10 years. One month prior to hospitalization, he developed a skin rash covering his entire body with blistering, soreness, severe weakness, fever, difficulty swallowing, and joint pain. Despite treatment (prednisolone, meropenem, linezolid, fluconazole), the patient’s condition worsened, leading to multiple organ failure and death. Postmortem biopsy revealed peripheral T-cell lymphoma of unspecifi ed type and exacerbation of chronic dermatosis. Conclusions. This case confirms the aggressive course and poor prognosis of peripheral T-cell lymphoma, highlighting the unsatisfactory results of standard therapy. The disease’s onset, with hyperthermia, polyarthralgia, and skin changes, complicated the diagnosis of lymphoma, partly due to the lack of awareness and oncologic suspicion of oncohematological pathology among general practitioners and dermatologists. This case demonstrates the usefulness of immunohistochemical examination of the lesion biopsy, determining the extent of lymphoproliferative bone marrow lesions, and determining patient management strategies.
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 483-485
Clinical masks of T-cell lymphoma
Some progress has been made in the study of the pathogenesis of peripheral T-cell lymphomas, which account for 10–15% of all non-Hodgkin’s lymphomas; however, diagnosis is diffi cult due to their rare occurrence and clinical and morphological diversity. Aim . to present data on the clinical course of peripheral T-cell lymphoma using a clinical example of patient Z. Material and methods. An analysis of literary sources was conducted and a case was presented demonstrating the difficulties in diagnosing non-Hodgkin’s T-cell lymphoma. Results and discussion. Patient Z., 56 years old, treated in a multidisciplinary hospital with the diagnosis of “Acute toxicoderma. Stevens–Johnson syndrome?” had been under the care of a dermatologist for dermatitis for 10 years. One month prior to hospitalization, he developed a skin rash covering his entire body with blistering, soreness, severe weakness, fever, difficulty swallowing, and joint pain. Despite treatment (prednisolone, meropenem, linezolid, fluconazole), the patient’s condition worsened, leading to multiple organ failure and death. Postmortem biopsy revealed peripheral T-cell lymphoma of unspecifi ed type and exacerbation of chronic dermatosis. Conclusions. This case confirms the aggressive course and poor prognosis of peripheral T-cell lymphoma, highlighting the unsatisfactory results of standard therapy. The disease’s onset, with hyperthermia, polyarthralgia, and skin changes, complicated the diagnosis of lymphoma, partly due to the lack of awareness and oncologic suspicion of oncohematological pathology among general practitioners and dermatologists. This case demonstrates the usefulness of immunohistochemical examination of the lesion biopsy, determining the extent of lymphoproliferative bone marrow lesions, and determining patient management strategies.
- 15 June 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 6,p. 22-28
Remaxol in perioperative infusion therapy for patients with calculous obstructive jaundice: a multiple-center observational study
Objective. To analyze the effect of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative infusion therapy (PITh) on bilirubinemia in patients with cholelithiasis (CL) complicated by obstructive jaundice (OJ). Material and methods. A multiple-center observational study included 283 patients with CL complicated by OJ. All patients underwent endoscopic papillosphincterotomy (EPST) with / without subsequent laparoscopic cholecystectomy (LC). Primary assessment of PITh efficacy was performed on days 6–7 after EPST. Bilirubinemia was compared with the day before EPST. A positive response to therapy was defined as normalization of total blood bilirubin or its reduction by 70%. Results. Factors influencing the efficacy of PITh in patients with OJ were identified. Positive response rate was 100% in patients receiving PITh with Remaxol proportion exceeding 80% (p=0.005). In case of Remaxol proportion >50%, positive response rate was 96.88% (p=0.001). In the group with Remaxol proportion 50% (p<0.001). Each 10% increase in proportion of Remaxol increased the probability of positive response to treatment by 13% (p=0.017). Conclusion. Inclusion of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative PITh for patients with OJ may have a positive effect on total blood bilirubin and increase the likelihood of normalization of this parameter or significant (by ≥70%) reduction in 6–7 days after successful EPST.
- 15 June 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 6,p. 22-28
Remaxol in perioperative infusion therapy for patients with calculous obstructive jaundice: a multiple-center observational study
Objective. To analyze the effect of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative infusion therapy (PITh) on bilirubinemia in patients with cholelithiasis (CL) complicated by obstructive jaundice (OJ). Material and methods. A multiple-center observational study included 283 patients with CL complicated by OJ. All patients underwent endoscopic papillosphincterotomy (EPST) with / without subsequent laparoscopic cholecystectomy (LC). Primary assessment of PITh efficacy was performed on days 6–7 after EPST. Bilirubinemia was compared with the day before EPST. A positive response to therapy was defined as normalization of total blood bilirubin or its reduction by 70%. Results. Factors influencing the efficacy of PITh in patients with OJ were identified. Positive response rate was 100% in patients receiving PITh with Remaxol proportion exceeding 80% (p=0.005). In case of Remaxol proportion >50%, positive response rate was 96.88% (p=0.001). In the group with Remaxol proportion 50% (p<0.001). Each 10% increase in proportion of Remaxol increased the probability of positive response to treatment by 13% (p=0.017). Conclusion. Inclusion of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative PITh for patients with OJ may have a positive effect on total blood bilirubin and increase the likelihood of normalization of this parameter or significant (by ≥70%) reduction in 6–7 days after successful EPST.
- Open Access
- 28 May 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (4) , 615-625
Gut Microbiome as a Modulator of Inflammation in Chronic Heart Failure
In recent years, the amount of scientific data indicating the key role of the gut microbiome in modulating immune responses that influence myocardial remodeling and the progression of chronic heart failure has been growing. Modulating the composition and function of the gut microbiome to reduce the severity of low-grade inflammation and slow the progression of chronic heart failure appears to be an innovative approach. This review aimed to analyze the role of the gut microbiome in cytokine-dependent inflammation in heart failure. Fifty-two sources containing data on associations between cytokine levels and gut microbiome bacterial genera in patients with heart failure, published from 1999 to 2025 in journals indexed in PubMed and eLibrary.ru, were analyzed. The review includes a description of modern molecular methods for studying the gut microbiome, along with their advantages and disadvantages. Changes in the taxonomic and quantitative composition of the gut microbiome and in the cytokine profile of patients with heart failure are presented. The data presented in the analyzed publications demonstrate a link between specific bacterial taxa and cytokine levels in certain phenotypic groups of chronic heart failure; however, the mechanisms underlying these relationships often remain the subject of further research. The identified limitations in the design of the reviewed studies, such as the presence of comorbidities, medication use, and unadjusted analyses that do not always account for confounding variables (diet and physical activity), underscore the need for further research to confirm these associations. Promising directions include research into disease-modifying treatment for chronic heart failure, including the development of methods to modulate the microbiota in order to reduce cytokine-mediated myocardial damage.
- 28 May 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (4) , 615-625
Open AccessGut Microbiome as a Modulator of Inflammation in Chronic Heart Failure
In recent years, the amount of scientific data indicating the key role of the gut microbiome in modulating immune responses that influence myocardial remodeling and the progression of chronic heart failure has been growing. Modulating the composition and function of the gut microbiome to reduce the severity of low-grade inflammation and slow the progression of chronic heart failure appears to be an innovative approach. This review aimed to analyze the role of the gut microbiome in cytokine-dependent inflammation in heart failure. Fifty-two sources containing data on associations between cytokine levels and gut microbiome bacterial genera in patients with heart failure, published from 1999 to 2025 in journals indexed in PubMed and eLibrary.ru, were analyzed. The review includes a description of modern molecular methods for studying the gut microbiome, along with their advantages and disadvantages. Changes in the taxonomic and quantitative composition of the gut microbiome and in the cytokine profile of patients with heart failure are presented. The data presented in the analyzed publications demonstrate a link between specific bacterial taxa and cytokine levels in certain phenotypic groups of chronic heart failure; however, the mechanisms underlying these relationships often remain the subject of further research. The identified limitations in the design of the reviewed studies, such as the presence of comorbidities, medication use, and unadjusted analyses that do not always account for confounding variables (diet and physical activity), underscore the need for further research to confirm these associations. Promising directions include research into disease-modifying treatment for chronic heart failure, including the development of methods to modulate the microbiota in order to reduce cytokine-mediated myocardial damage.
- Open Access
- 19 May 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (2S) , 4746
Nikolay S. Korotkov is a lonely and extraordinary star in the firmament of the great names of world science (on the 120th anniversary of the creation of the sound detection method blood pressure by Russian surgeon Nikolay S. Korotkov)
It has been 120 years since the Russian surgeon Nikolay S. Korotkov, during the war (the war with Japan), in the field conditions, created a sound method for determining blood pressure in humans. The method later brought worldwide fame to its creator, through him to the entire Russian science, and still remains the "golden" standard for non-invasive measurement of blood pressure in humans. The process of creating the method itself (from the point of view of some scientists, being ambiguous: random — not random?) It is undoubtedly of great interest as an example of a fruitful combination of intelligence, hard work, perseverance, luck and timely help from a senior mentor. Korotkov's method began to be used abroad after the article by J. Erlander was born in the USA (in 1916) and then he conquered the whole world, but In Russia, for unknown reasons, the name of Nikolay S. Korotkov was hushed up for many years. After being informed about the creation of the method, i.e. after 1905, N. S. Korotkov never used his method again, he did not create a new field of medicine based on his method, did not establish scientific schools in either surgery or therapy, did not obtain patents, and did not have any students, monographs, or articles, either In Russia or abroad. He died at the age of 46 from a massive pulmonary hemorrhage, having suffered from bilateral pulmonary tuberculosis. Therefore, Nikolay S. Korotkov's "star" is "lonely" and "extraordinary". The "extraordinary" nature of Nikolay S. Korotkov's phenomenon lies in the social paradox that if there had been no war, the method itself would not have been created. The article suggests understanding Nikolay S. Korotkov's phenomenon by delving into the events of 120 years ago. Korotkov's "path", which is unusual in many ways, can serve as an example for scientific endeavors even today.
- 19 May 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (2S) , 4746
Open AccessNikolay S. Korotkov is a lonely and extraordinary star in the firmament of the great names of world science (on the 120th anniversary of the creation of the sound detection method blood pressure by Russian surgeon Nikolay S. Korotkov)
It has been 120 years since the Russian surgeon Nikolay S. Korotkov, during the war (the war with Japan), in the field conditions, created a sound method for determining blood pressure in humans. The method later brought worldwide fame to its creator, through him to the entire Russian science, and still remains the "golden" standard for non-invasive measurement of blood pressure in humans. The process of creating the method itself (from the point of view of some scientists, being ambiguous: random — not random?) It is undoubtedly of great interest as an example of a fruitful combination of intelligence, hard work, perseverance, luck and timely help from a senior mentor. Korotkov's method began to be used abroad after the article by J. Erlander was born in the USA (in 1916) and then he conquered the whole world, but In Russia, for unknown reasons, the name of Nikolay S. Korotkov was hushed up for many years. After being informed about the creation of the method, i.e. after 1905, N. S. Korotkov never used his method again, he did not create a new field of medicine based on his method, did not establish scientific schools in either surgery or therapy, did not obtain patents, and did not have any students, monographs, or articles, either In Russia or abroad. He died at the age of 46 from a massive pulmonary hemorrhage, having suffered from bilateral pulmonary tuberculosis. Therefore, Nikolay S. Korotkov's "star" is "lonely" and "extraordinary". The "extraordinary" nature of Nikolay S. Korotkov's phenomenon lies in the social paradox that if there had been no war, the method itself would not have been created. The article suggests understanding Nikolay S. Korotkov's phenomenon by delving into the events of 120 years ago. Korotkov's "path", which is unusual in many ways, can serve as an example for scientific endeavors even today.
- 22 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2S)
Integration of artificial intelligence technologies in electrocardiogram analysis: current trends and prospects. A review
A trend of the last decade has been the use of artificial intelligence (AI) technologies aimed at developing preventive medicine by optimizing the use of healthcare resources, including reducing the burden on medical personnel and improving the accuracy of medical data analysis. This review highlights AI-based tools, current trends, and prospects for their application in interpreting electrocardiogram patterns to identify changes often missed by standard routine analysis. Accumulated data from several studies indicate the prognostic value of AI-based models trained on sinus rhythm electrocardiograms in the diagnosis of paroxysmal atrial fibrillation, hypertrophic cardiomyopathy, and heart failure.
- 22 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2S)
Integration of artificial intelligence technologies in electrocardiogram analysis: current trends and prospects. A review
A trend of the last decade has been the use of artificial intelligence (AI) technologies aimed at developing preventive medicine by optimizing the use of healthcare resources, including reducing the burden on medical personnel and improving the accuracy of medical data analysis. This review highlights AI-based tools, current trends, and prospects for their application in interpreting electrocardiogram patterns to identify changes often missed by standard routine analysis. Accumulated data from several studies indicate the prognostic value of AI-based models trained on sinus rhythm electrocardiograms in the diagnosis of paroxysmal atrial fibrillation, hypertrophic cardiomyopathy, and heart failure.
- Open Access
- 13 March 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (2) , 241-250
Autonomic nervous system in chronic heart failure
The autonomic nervous system is a critical regulator of cardiovascular function, and its imbalance contributes substantially to cardiovascular diseases and their complications. This work aimed to analyze studies addressing the impact of the autonomic nervous system on the course and prognosis of chronic heart failure, including in patients with comorbidities. The review included 47 papers published between 2000 and 2025 in PubMed and eLIBRARY.RU journals that investigated the role of the autonomic nervous system in chronic heart failure. The article discusses the origins of heart rate variability assessment and diagnostic tools for evaluating autonomic nervous system function in various cardiovascular diseases. The review describes the pathogenetic mechanisms underlying changes in autonomic status and the key parameters used to assess it, predominantly based on noninvasive time- and frequency-domain heart rate variability analysis for a more accurate evaluation of adaptation level, stress reactivity, and the degree of autonomic imbalance. Data on age- and sex-related differences in heart rate variability in patients with chronic heart failure are presented, including those with comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, and diabetes mellitus. Evidence is provided to support the prognostic value of heart rate variability parameters that influence disease course and cardiovascular risk in patients with chronic heart failure. Investigating the pathogenetic mechanisms underlying autonomic dysfunction in patients with cardiovascular diseases is relevant for developing new therapeutic approaches to restore autonomic nervous system balance. Time- and frequency-domain heart rate variability analysis is an accessible and convenient noninvasive method that can be used in a wide patient population to provide valuable information for personalized therapeutic strategies.
- 13 March 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (2) , 241-250
Open AccessAutonomic nervous system in chronic heart failure
The autonomic nervous system is a critical regulator of cardiovascular function, and its imbalance contributes substantially to cardiovascular diseases and their complications. This work aimed to analyze studies addressing the impact of the autonomic nervous system on the course and prognosis of chronic heart failure, including in patients with comorbidities. The review included 47 papers published between 2000 and 2025 in PubMed and eLIBRARY.RU journals that investigated the role of the autonomic nervous system in chronic heart failure. The article discusses the origins of heart rate variability assessment and diagnostic tools for evaluating autonomic nervous system function in various cardiovascular diseases. The review describes the pathogenetic mechanisms underlying changes in autonomic status and the key parameters used to assess it, predominantly based on noninvasive time- and frequency-domain heart rate variability analysis for a more accurate evaluation of adaptation level, stress reactivity, and the degree of autonomic imbalance. Data on age- and sex-related differences in heart rate variability in patients with chronic heart failure are presented, including those with comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, and diabetes mellitus. Evidence is provided to support the prognostic value of heart rate variability parameters that influence disease course and cardiovascular risk in patients with chronic heart failure. Investigating the pathogenetic mechanisms underlying autonomic dysfunction in patients with cardiovascular diseases is relevant for developing new therapeutic approaches to restore autonomic nervous system balance. Time- and frequency-domain heart rate variability analysis is an accessible and convenient noninvasive method that can be used in a wide patient population to provide valuable information for personalized therapeutic strategies.
- Open Access
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 64-69
Heart failure in Duchenne's progressive muscular dystrophy (case report)
Progressive Duchenne muscular dystrophy is a common X-linked recessive myopathy caused by a mutations in the gene encoding dystrophin. Duchenne muscular dystrophy is characterized by damage to the heart muscle with conduction and rhythm disturbances, and the development of dilated cardiomyopathy, which may be asymptomatic. The development of heart failure determines the unfavorable prognosis of patients with Duchenne muscular dystrophy. Insufficient awareness of physicians about the characteristics of heart damage in Duchenne muscular dystrophy creates the prerequisites for describing interesting clinical observations. The article presents a clinical observation of the development of dilated cardiomyopathy and heart failure with a low left ventricular ejection fraction in a 19-year-old male patient with Duchenne muscular dystrophy. The dynamics of Duchenne muscular dystrophy progression from the moment of diagnosis to the development of decompensated heart failure are described. The article presents clinical course data, laboratory parameters, electrocardiography and echocardiography data in dynamics. The article presents diagnostic criteria for Duchenne muscular dystrophy, prospects for therapy aimed at correcting the genetic defect by replacing, modifying or reparating the dystrophin gene. The presented case demonstrates the need for a personalized multidisciplinary approach to a patient with Duchenne muscular dystrophy, with the participation of an orthopedic surgeon, pulmonologist, cardiologist, endocrinologist, and ophthalmologist.
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 64-69
Open AccessHeart failure in Duchenne's progressive muscular dystrophy (case report)
Progressive Duchenne muscular dystrophy is a common X-linked recessive myopathy caused by a mutations in the gene encoding dystrophin. Duchenne muscular dystrophy is characterized by damage to the heart muscle with conduction and rhythm disturbances, and the development of dilated cardiomyopathy, which may be asymptomatic. The development of heart failure determines the unfavorable prognosis of patients with Duchenne muscular dystrophy. Insufficient awareness of physicians about the characteristics of heart damage in Duchenne muscular dystrophy creates the prerequisites for describing interesting clinical observations. The article presents a clinical observation of the development of dilated cardiomyopathy and heart failure with a low left ventricular ejection fraction in a 19-year-old male patient with Duchenne muscular dystrophy. The dynamics of Duchenne muscular dystrophy progression from the moment of diagnosis to the development of decompensated heart failure are described. The article presents clinical course data, laboratory parameters, electrocardiography and echocardiography data in dynamics. The article presents diagnostic criteria for Duchenne muscular dystrophy, prospects for therapy aimed at correcting the genetic defect by replacing, modifying or reparating the dystrophin gene. The presented case demonstrates the need for a personalized multidisciplinary approach to a patient with Duchenne muscular dystrophy, with the participation of an orthopedic surgeon, pulmonologist, cardiologist, endocrinologist, and ophthalmologist.
- Open Access
- 25 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 810-818
Cardiovascular diseases and personality type
Cardiovascular diseases are a leading cause of death, especially in developed countries. As new evidence-based medical findings emerge, the range of risk factors for cardiovascular diseases expands. Modern cardiology acknowledges that the development of a cardiovascular risk management system is critical. Psychological aspects, including personality, emotional regulation, and associated behaviors, have been found to contribute to cardiovascular disease onset and progression. This review summarizes and systematizes information from clinical studies and systematic reviews published through PubMed and eLIBRARY.RU. These databases were searched for articles detailing how personality types may influence the clinical course and prognosis of cardiovascular diseases through the interplay with various biological and behavioral factors. Moreover, this study provides an overview of personality types A, B, AB, and D and the methods for their identification. These methods include the Jenkins and Wasserman–Gumenyuk questionnaires, which were adapted for the Russian-speaking population to align with the cultural context, focusing on identifying personality type D (DS-14). Enhancing medical professionals’ awareness of personality traits and their role in cardiovascular diseases can facilitate deeper understanding of the causes of patient maladaptation and improve the effectiveness of strategies for preventing complications. Targeted and prompt psychotherapeutic interventions will contribute to the modification of negative aspects, decrease cardiovascular event risk, increase treatment compliance, and increase life expectancy.
- 25 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 810-818
Open AccessCardiovascular diseases and personality type
Cardiovascular diseases are a leading cause of death, especially in developed countries. As new evidence-based medical findings emerge, the range of risk factors for cardiovascular diseases expands. Modern cardiology acknowledges that the development of a cardiovascular risk management system is critical. Psychological aspects, including personality, emotional regulation, and associated behaviors, have been found to contribute to cardiovascular disease onset and progression. This review summarizes and systematizes information from clinical studies and systematic reviews published through PubMed and eLIBRARY.RU. These databases were searched for articles detailing how personality types may influence the clinical course and prognosis of cardiovascular diseases through the interplay with various biological and behavioral factors. Moreover, this study provides an overview of personality types A, B, AB, and D and the methods for their identification. These methods include the Jenkins and Wasserman–Gumenyuk questionnaires, which were adapted for the Russian-speaking population to align with the cultural context, focusing on identifying personality type D (DS-14). Enhancing medical professionals’ awareness of personality traits and their role in cardiovascular diseases can facilitate deeper understanding of the causes of patient maladaptation and improve the effectiveness of strategies for preventing complications. Targeted and prompt psychotherapeutic interventions will contribute to the modification of negative aspects, decrease cardiovascular event risk, increase treatment compliance, and increase life expectancy.